top of page

CUSTOM HUMAN 3D IN VITRO MODELS
and NAMs assay development

4Dcell develops customized human 3D tissue models and New Approach Methodology (NAM) assays for drug discovery and preclinical research.4Dcell develops customized human 3D tissue models and New Approach Methodology (NAM) assays for drug discovery and preclinical research.

 

Combining SmartContractility™ and SmartSphero™ technologies, we help pharmaceutical and biotechnology companies design, characterize and apply human in vitro models tailored to their biological questions.

​

From tissue engineering to functional characterization and compound testing, our Design Office works alongside your scientific team to develop fit-for-purpose experimental solutions.

TWO ENGINEERING PLATFORMS
FOR CUSTOM HUMAN IN VITRO TISSUE MODELS  

Developing a relevant human in vitro model requires more than assembling cells into a 3D structure. Tissue architecture, mechanical environment, cellular organization and measurable biological function must be considered together.

​

4Dcell builds on two complementary technologies to develop custom contractile tissues, spheroids and organoids, selecting the most appropriate platform according to the biological and experimental requirements of each project.

3D Contractile Tissue Models — SmartContractility™

SmartContractility™ enables the self-assembly of 3D ring-shaped tissues around a central deformable pillar, providing a controlled mechanical environment for studying tissue contraction.

By tracking tissue deformation, the platform supports quantitative analysis of contraction amplitude, contraction and relaxation kinetics, and beating activity where applicable. Mechanical measurements can be established according to the tissue model and assay calibration.

​

Originally developed for cardiac and skeletal muscle applications, this engineering approach provides a foundation for custom models of mechanically active tissues, including smooth muscle and other contractile cell systems.

​

Potential applications include:

  • Skeletal muscle function and drug response

  • Smooth muscle contractility

  • Uterine and reproductive tissue contractility

  • Disease-related changes in tissue mechanics

  • Functional efficacy and toxicity studies

​

Cell composition, tissue maturation, stimulation conditions and readouts are defined and assessed according to the intended use of each model.

3D Contractile Tissue Models — SmartContractility™

SmartSphero™ is a hydrogel-based microwell technology designed to support controlled self-assembly of spheroids and organoids in multiwell plates.

​

Its proprietary Anchoring Point Technology (APT®) retains individual microtissues at predictable positions, helping prevent displacement during medium exchange and experimental handling. Multiple microtissues can be generated within the same well and maintained on a common focal plane, facilitating microscopy, repeated imaging and quantitative analysis.

​

The platform provides an engineering foundation for developing customized multicellular models, including:

  • Human tissue-specific spheroids and organoids

  • Patient-derived and disease-relevant models

  • Multicellular co-culture systems

  • Models for compound response and toxicity assessment

  • Imaging-based and molecular phenotyping studies

​

Cell sources, culture conditions, tissue architecture and experimental endpoints are adapted to the biological question and assessed during model development.

CUSTOM NAM APPLICATIONS
FOR DRUG DISCOVERY AND PRECLINICAL RESEARCH

Our Design Office develops experimental models and assays around specific research needs, particularly when existing in vitro approaches do not adequately capture the biological response of interest.

​

Depending on the model and its level of qualification, applications may include drug efficacy studies, safety assessment, disease modeling and mechanism-of-action investigations.

Drug efficacy & mechanism of action

Investigate how candidate compounds affect tissue function, cellular organization or molecular pathways using human 3D models selected for the therapeutic mechanism of interest.

Experimental endpoints can be adapted to capture functional changes, concentration-dependent responses and mechanistic effects relevant to compound characterization.

Safety & Toxicity Assessment

Develop human in vitro assays to investigate unwanted compound effects on tissue viability, morphology and function.

Depending on the model and experimental objectives, studies may combine functional measurements with imaging and molecular endpoints to characterize compound-induced changes under defined exposure conditions.

Disease Modeling & Assay Development

Develop disease-relevant human 3D models using appropriate cell sources, multicellular organization and experimental conditions.

Our team supports model feasibility, tissue formation, phenotype characterization and the selection of measurable endpoints before progressing to compound testing.

The objective is to establish an experimental system suited to the disease mechanism and scientific decision being investigated, with performance assessed for the intended use.

FROM BIOLOGICAL QUESTION TO FIT-FOR-PURPOSE ASSAY

Our Design Office follows a structured development process, from initial project definition to model characterization and experimental testing.

Each stage is designed to establish whether the proposed model and assay can provide meaningful, reproducible data for the intended research application.

Gate 0 — Project Scoping & Model Definition

We work with your scientific team to define the biological question, intended use, cell sources and experimental requirements.

Together, we select the appropriate tissue engineering technology, identify relevant functional or molecular endpoints and establish the feasibility objectives and success criteria.

Outcome: A defined experimental strategy, model specifications and development plan.

Gate 1 — Model Engineering & Functional Characterization

We develop and optimize the selected 3D model, including tissue assembly, culture conditions, cellular organization and maturation where applicable.

Model characterization may include morphology, viability, functional activity and reproducibility assessment. Quality-control criteria and analytical methods are established according to the intended experimental use.

Outcome: A characterized model with documented methods, performance observations and identified limitations.

Gate 2 — Compound Testing & Assay Qualification

Once the model demonstrates suitable performance, we design and execute compound-testing studies using the selected experimental endpoints.

Depending on the project, this stage may include reference compounds, concentration-response studies, statistical analysis and further assessment of assay variability, sensitivity and reproducibility.

Outcome: Quantitative experimental data, scientific interpretation and a documented assessment of assay performance within the tested conditions.

FUNCTIONAL READOUTS, DATA ANALYSIS
& STUDY DELIVERABLES

A useful human in vitro model must generate measurements that address the scientific question being investigated.

 

Our Design Office combines tissue engineering with experimental characterization and quantitative analysis. Readouts are selected according to the tissue model, biological mechanism and intended use of the assay.

Available Experimental Readouts

Depending on model compatibility and project scope, experimental measurements may include:

  • Contractility and tissue mechanics: contraction amplitude, tissue deformation, contraction and relaxation kinetics.

  • Morphology and tissue organization: tissue geometry, structural integrity and imaging-based phenotypes.

  • Cell viability and functional response: viability measurements and changes following compound exposure.

  • Molecular characterization: gene expression, qPCR, RNA sequencing and selected biomarker analysis.

  • Compound response: concentration-dependent effects, response variability and quantitative comparison with controls.

Additional or model-specific endpoints can be evaluated during the feasibility phase.

Study Deliverables

Study deliverables are agreed upon during project definition and may include:

  • Experimental study design and testing protocols

  • Model characterization and quality-control results

  • Quantitative datasets and statistical analysis

  • Dose-response curves and functional measurements

  • Scientific reports with interpretation and study limitations

  • Recommendations for assay optimization or subsequent studies

Raw data, detailed protocols and additional documentation can be included according to the agreed project scope.

TECHNOLOGY FOUNDATION & SCIENTIFIC EVIDENCE

4Dcell's custom model development capabilities build on established tissue engineering technologies combining microfabrication, controlled 3D cell organization and quantitative biological analysis.

​

These technologies have been applied to different tissue models, providing an engineering foundation for the development of new experimental systems.

Ring-Shaped Tissue Engineering — SmartContractility™

The SmartContractility™ approach has been demonstrated in human cardiac microtissues, where iPSC-derived cardiomyocytes self-assemble into 3D ring-shaped tissues enabling quantitative assessment of contractile function.

This application, described in peer-reviewed research, illustrates how controlled tissue geometry and mechanical measurements can be combined in a multiwell format.

The development of non-cardiac contractile models builds on this engineering principle, with biological performance and assay qualification assessed separately for each new tissue type.

Pancreatic β-Cell Spheroids for Functional Drug Screening — SmartSphero™

In a peer-reviewed study published in eLife (Robben et al., 2026), 4Dcell and KU Leuven demonstrated the use of SmartSphero™ technology to develop a high-throughput functional assay using pancreatic β-cell spheroids.

The platform enabled the formation of 19 uniformly shaped and anchored MIN6 β-cell spheroids per well in a 96-well plate, allowing simultaneous monitoring of calcium oscillations across up to 1,824 individual spheroids.

The study demonstrated glucose-dependent calcium responses correlated with insulin secretion, and characterized the pharmacological effects of compounds targeting KATP and TRPM3 ion channels.

These findings illustrate how SmartSphero™ can support the development of reproducible 3D cellular models combining controlled tissue organization, high-content imaging and functional drug-response measurements.

FREQUENTLY ASKED QUESTIONS

DEVELOP A HUMAN 3D IN VITRO MODEL

Looking for a human in vitro model that goes beyond standard assay formats?

​

Share your biological question, cell model or experimental challenge with our scientific team. We will help you evaluate the most appropriate tissue engineering approach, identify relevant endpoints and define a development strategy aligned with your research objectives.

bottom of page